Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study.

Autor: Hoogendoorn M; Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: hoogendoorn@imta.eur.nl., Jowett S; Health Economics Unit, University of Birmingham, Birmingham, England, UK., Dickens AP; Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK., Jordan R; Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK., Enocson A; Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK., Adab P; Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK., Versteegh M; Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands., Mölken MR; Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2021 Nov; Vol. 24 (11), pp. 1667-1675. Date of Electronic Publication: 2021 Aug 04.
DOI: 10.1016/j.jval.2021.05.006
Abstrakt: Objectives: A respiratory bolt-on dimension for the EQ-5D-5L has recently been developed and valued by the general public. This study aimed to validate the EQ-5D-5L plus respiratory dimension (EQ-5D-5L+R) in a large group of patients with chronic obstructive pulmonary disease (COPD).
Methods: Validation was undertaken with data from the Birmingham COPD Cohort Study, a longitudinal UK study of COPD primary care patients. Data on the EQ-5D-5L+R were collected from 1008 responding participants during a follow-up questionnaire in 2017 and combined with (previously collected) data on patient and disease characteristics. Descriptive and correlation analyses were performed on the EQ-5D-5L+R dimensions and utilities, in relation to COPD characteristics and compared with the EQ-5D-5L without respiratory dimension. Multivariate regression models were estimated to test whether regression coefficients of clinical characteristics differed between the EQ-5D-5L+R utility and the EQ-5D-5L utility.
Results: Correlation coefficients for the EQ-5D-5L+R utility with COPD parameters were slightly higher than the EQ-5D-5L utility. Both instruments displayed discriminant validity but analyses in clinical subgroups of patients showed larger absolute differences in utilities for the EQ-5D-5L+R. In the multivariate analyses, only the coefficient for the COPD Assessment Test score was higher for the model using the EQ-5D-5L+R utility as outcome.
Conclusions: This study showed that the addition of a respiratory domain to the EQ-5D-5L led to small improvements in the instrument's performance. Comparability of the EQ-5D across diseases, currently considered one of its strengths, would have to be traded off against a modest improvement in utility difference when adding the respiratory dimension.
(Copyright © 2021 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: